South Dakota Investment Council Has $5,852,000 Position in Eli Lilly and Company (LLY)

South Dakota Investment Council held its stake in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 69,570 shares of the company’s stock at the end of the first quarter. South Dakota Investment Council’s holdings in Eli Lilly and were worth $5,852,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in LLY. Heritage Trust Co purchased a new position in shares of Eli Lilly and during the first quarter worth approximately $135,000. Penserra Capital Management LLC raised its position in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares in the last quarter. Crestwood Advisors Group LLC purchased a new position in shares of Eli Lilly and during the first quarter worth approximately $179,000. Sandy Spring Bank raised its position in shares of Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after buying an additional 750 shares in the last quarter. Finally, Coldstream Capital Management Inc. purchased a new position in shares of Eli Lilly and during the first quarter worth approximately $200,000. 75.59% of the stock is owned by hedge funds and other institutional investors.

Shares of Eli Lilly and Company (NYSE:LLY) traded down 0.09% during midday trading on Friday, hitting $78.79. 2,171,482 shares of the company were exchanged. The stock has a market cap of $83.12 billion, a PE ratio of 34.09 and a beta of 0.34. The stock’s 50-day moving average is $81.83 and its 200-day moving average is $81.93. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the prior year, the company posted $0.86 earnings per share. Eli Lilly and’s revenue was up 7.8% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.64%. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

LLY has been the topic of a number of recent analyst reports. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Citigroup Inc. reiterated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a report on Tuesday, July 4th. Jefferies Group LLC reiterated a “buy” rating and issued a $92.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a report on Saturday, April 29th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $92.00 price objective on shares of Eli Lilly and in a report on Tuesday, May 16th. Finally, Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a report on Monday, July 17th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $87.92.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the sale, the insider now owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the sale, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. Insiders sold 669,733 shares of company stock worth $55,845,287 over the last 90 days. 0.20% of the stock is currently owned by corporate insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.